07:00 , Sep 19, 2016 |  BC Week In Review  |  Financial News

Advantagene completes venture financing

Advantagene Inc., Auburndale, Mass.   Business: Cancer   Date completed: 2016-09-12   Type: Venture financing   Raised: $14.2 million   ...
07:00 , Sep 12, 2016 |  BC Extra  |  Financial News

Advantagene raises $14.2M

Immuno-oncology company Advantagene Inc. (Auburndale, Mass.) raised $14.2 million in a series A round from undisclosed investors. The National Securities Corp. subsidiary of National Holdings Corp. (NASDAQ:NHLD) was the placement agent. The funding is Advantagene's...
07:00 , Jul 23, 2015 |  BC Innovations  |  Tools & Techniques

Gene therapy's coming of age

After more than 20 years of trial and error in gene therapy, the field is taking off with one product approved in Europe, several poised to enter the market in the U.S., a surge of...
07:00 , Aug 9, 2012 |  BC Innovations  |  Targets & Mechanisms

Screening for immunogenic cell death

French researchers have used a fluorescence-based screening platform to identify small molecules that induced immunogenic cell death in mouse tumors.1 Next, the group plans to test the best hits in a Phase I/II trial to...
07:00 , May 30, 2011 |  BC Week In Review  |  Clinical News

ProstAtak: SPA received

Advantagene received an SPA from FDA for a planned double-blind, placebo-controlled, U.S. Phase III trial to evaluate 3 injections of ProstAtak followed by oral valacyclovir and radiation therapy in 711 patients. The company plans to...